<DOC>
	<DOCNO>NCT02345213</DOCNO>
	<brief_summary>The purpose study confirm efficacy Aricept patient dementia Lewy body ( DLB ) .</brief_summary>
	<brief_title>A Post-Marketing Clinical Study Aricept Patients With Dementia With Lewy Bodies ( DLB )</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients diagnose probable DLB accord diagnostic criterion DLB 2 . Patients caregiver throughout study submit write consent cooperate study , routinely stay patient least 3 day week ( least 4 hour day ) , provide patient ' information necessary study , assist treatment compliance , escort patient require visit study institution 3 . Clinical Dementia Rating ( CDR ) score great equal 0.5 4 . MiniMental State Examination ( MMSE ) score great equal 10 less equal 26 Exclusion Criteria 1 . Patients diagnose Parkinson 's disease dementia ( PDD ) 2 . Patients receive antidementia drug therapy within 12 week start observation period 3 . Patients complication serious neuropsychiatric disease ( ) stroke , brain tumor , schizophrenia , epilepsy , normal pressure hydrocephalus , mental retardation , brain trauma unconsciousness , history brain surgery causing unrecovered deficiency 4 . Patients severe extrapyramidal disorder ( Hoehn Yahr stag score great equal IV ) 5 . Patients whose systolic blood pressure le 90 mmHg pulse rate le 50 beats/minute screen test</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DLB</keyword>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Lewy Body Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>E2020</keyword>
	<keyword>Donepezil</keyword>
	<keyword>Aricept</keyword>
</DOC>